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Introduction
Ventilator-associated bacterial pneumonia (VAP) is a major
threat to the recovery of patients receiving mechanical ven-
tilation, and is one of the most important intensive care unit
(ICU)-acquired infections in mechanically ventilated
patients. In the European Prevalence of Infection in Inten-
sive Care (EPIC) study, VAP was the most frequent infec-
tion, with about 45% of all infections in ICUs in Europe [1].
BAL = bronchoalveolar lavage; CFU = colony-forming units; CPIS = Clinical Pulmonary Infection Score; ICU = intensive care unit; PSB = protected
specimen brush; TBS = tracheobronchial secretion; VAP = ventilator-associated pneumonia.
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Abstract
Background: Ventilator-associated bacterial pneumonia (VAP) is a important intensive care unit (ICU)-
acquired infection in mechanically ventilated patients. Early and correct diagnosis of VAP is difficult but
is an urgent challenge for an optimal antibiotic treatment. The aim of the study was to evaluate the
incidence and microbiology of ventilator-associated pneumonia and to compare three quantitative
bronchoscopic methods for diagnosis.
Methods: A prospective, open, epidemiological clinical study was performed in a surgical ICU. In a
prospective study, 279 patients admitted to a 14-bed surgical ICU during a 1-year period were
evaluated with regard to VAP. Three quantitative culture bronchoscopic techniques for identifying the
etiological agent were compared [bronchoalveolar lavage (BAL), protected specimen brush (PSB) and
bronchoscopic tracheobronchial secretion (TBS)].
Results: Among 103 long-term ventilated patients, 49 (48%) developed one or more VAPs (a total of
60 VAPs). The incidence was 24 VAPs per 100 ventilated patients or 23 VAPs per 1000 ventilator
days. BAL, PSB and TBS with quantitative measurements were equivalent in identifying the bacterial
etiology. The VAP was caused predominantly by Staphylococcus aureus in 38% of cases, followed by
Pseudomonas aeruginosa in 10%, Haemophilus influenzae in 10% and Klebsiella sp. in 9%. We did
not find an increased mortality rate in patients undergoing long-term ventilation who acquired VAP in
comparison with patients without VAP.
Conclusion: For the identification of the microbiological etiology of VAP, one of three available
bronchoscopic methods analysed by quantitative measurements is sufficient. In our study, quantitative
bronchoscopic tracheal secretion analysis was very promising. Before accepting this method as a
standard technique, other studies will have to confirm our results.
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The incidence of bronchopulmonary infections in ICUs
reported in a review by George et al [2] was 12.5 cases
per 1000 patient days, but device-related incidence was
20.5 cases per 1000 patient ventilator days. Today there is
no standard test for the diagnosis of VAP and no standard
method to exclude pulmonary infections in mechanically
ventilated patients with fever and multiorgan dysfunction
syndrome or multiorgan failure. Even the post-mortem his-
tological diagnosis of VAP is uncertain [3]. The lack of cer-
tainty in the diagnosis of VAP has led to many different
clinical and microbiological approaches in the past.
The bronchoscopic methods bronchoalveolar lavage
(BAL) and protected specimen brush (PSB) are well-stan-
dardised and widely accepted invasive diagnostic tech-
niques for identifying the etiological pathogen of VAP [4].
In a recent study, Heyland et al [5] found that invasive
diagnostic testing might increase the confidence of physi-
cians in the diagnosis and management of VAP as well as
decreased antibiotic usage and lower mortality.
In the past the impracticability of bronchoscopic methods
in ICUs, and also their cost, has led to other strategies in
clinical use such as nonbronchoscopic techniques with
catheters or mini-lavage [6,7].
The early and accurate diagnosis of VAP is difficult, but
because of the increasing problem of multi-resistant
pathogens in many ICUs it constitutes an urgent challenge
as well as a rational basis for an optimal antibiotic treat-
ment. It is especially difficult to distinguish VAP from other
causes of fever and inflammatory reaction in ICU patients
[4]. During treatment in an ICU, the accuracy of VAP diag-
nosis has to be checked and if necessary amended.
A fatal outcome is frequently observed in patients requir-
ing mechanical ventilation for more than 48 h. VAP is a fre-
quent complication in these cases. Several investigators
have assumed that VAP has a direct causal influence on
mortality [8]. However, it has not been clearly demon-
strated that VAP is directly responsible for mortality [9]. In
a matched controlled cohort study, Papazian et al [10]
found no significant difference in mortality between
mechanically ventilated patients with and without VAP.
In a prospective clinical approach, we examined the epidemi-
ology and microbiological findings of VAP in a surgical ICU
and compared the results of three different bronchoscopic
methods with quantitative measurements to identify the etio-
logical pathogens. In our ICU bronchoscopy is performed
quite frequently in patients suspected of having VAP, and we
were interested in a simple specimen sampling method.
Materials and methods
In a prospective study we evaluated the epidemiology and
microbiological etiology of VAP in a 14-bed surgical ICU of a
1000-bed general hospital during a one-year period (from 1
January to 31 December 1996). We collected demographic
data, duration of ventilator therapy, length of ICU stay,
APACHE (Acute Physiology And Chronic Health Evaluation)
II score at the time of admission, and occurrence of VAP.
With the use of the clinical and X-ray criteria described
below we divided the patients into two groups: (1) long-
term ventilated patients (more than 48 h of mechanical
ventilation) who developed VAP (case group) and (2)
long-term ventilated patients without VAP (control group).
Reasons for admission were principally acute respiratory
failure with requirement of mechanical ventilation; coma;
or, rarely, disorders of other basic vital functions such as
renal failure, coagulopathy and shock. The surgical disci-
pline for the treatment of underlying disease, duration of
treatment and mechanical ventilation, demographic and
physiological data, outcome and, if necessary, cause of
death were recorded and compared (Table 1).
Definition
The VAP was defined by means of clinical and radiological
criteria and by using the Clinical Pulmonary Infection
Score (CPIS) [7]. These criteria were as follows:
1. A new and persistent infiltration in the chest X-ray in
patients mechanically ventilated for more than 48 h.
2. Body temperature above 38.5 or below 36°C.
3. White cell count above 12,000/ml or below 4000/ml.
4. Purulent tracheobronchial secretion (TBS).
5. Impairment of pulmonary function as defined by the
PaO2/FiO2 ratio.
6. The absence of alternative sources of infection such as
urinary tract infection or peritonitis.
A score of 6 or more points using the CPIS criteria is
needed to define pneumonia.
Bronchoscopy
In each case of definite pneumonia by CPIS score we per-
formed bronchoscopy on the anaesthetized and paralysed
patient to collect samples from the respiratory tract for
quantitative microbiological examination in a specific, con-
stant sequence and with the following thresholds: TBS,
105 and 106 colony-forming units (CFU)/ml); PSB,
103 CFU/ml; BAL, 104 CFU/ml.
After these procedures, patients with CPIS criteria for pneu-
monia who had not received antibiotic therapy were given
antibiotics. The antibiotic treatment was changed when
appropriate depending on the resistance of the bacteria.
First, TBS was aspirated through the working channel of the
bronchoscope (Olympus Optical Co. Ltd, Tokyo, Japan),
diluted 1:1 with sterile physiological saline solution and
vortex-mixed. Then the brush of the PSB (microbiology
specimen brush; Boston Scientific Corporation, Watertown,c
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MA, USA) was severed aseptically into 1 ml of transport
medium (sterile physiological saline solution). After this pro-
cedure, BAL was performed in the wedge position with 120
ml of sterile physiological saline solution in six aliquots, of
which the first recovered aliquot was used for rinsing the
working channel of the bronchoscope and then rejected.
Microbiological analysis
Acquired specimens were transferred to the microbiologi-
cal laboratory within 45 min. Direct microscopic analysis
of respiratory samples is the first and very important com-
ponent of microbiological diagnosis of VAP. We used
Gram stain to detect microorganisms. By using a modified
twofold dilution scheme we determined the quantitative
culture in CFU/ml. The media and incubation conditions
were appropriate for the cultivation of the most probable
respiratory pathogens. The set-up included blood agar as
a general non-selective medium, chocolate agar for
Haemophilus, bile-chrysoidine agar for enterics, and
anaerobic media [11]. The direct examination of smears
was not performed in this study.
Statistics
The results are presented as medians or means ± stan-
dard deviation. Differences in parameters and in the fre-
quency of characteristic features were assessed with the
U test of Wilcoxon, Mann and Whitney, and with the c2
test. The grade of concordance of the different sampling
methods was established with the concordance index of
Cohen’s Kappa, k =( P0 – Pe)/(1 – Pe), P0 =( a + d)/n and
Pe =[ ( a + b)(a + c)+( c + d)(b + d)]/n2.
For all statistical tests used, P < 0.05 was considered sta-
tistically significant. The data were processed with commer-
cially available statistical software (SPSS 6.1 for Windows).
Results
Patient demographics
Over the 1-year study period, 103 patients (of a total of
279 admitted patients) required mechanical ventilation
for more than 48 h; 245 of the 279 patients were
mechanically ventilated.
The reasons for ICU admission were major abdominal or tho-
racic surgery in 87 cases (31.2%), multiple trauma or severe
head injury in 58 cases (20.8%), sepsis in 29 cases
(10.3%), aortic surgery in 21 cases (7.5%) and others,
including postoperative monitoring, pulmonary embolism,
cerebral function disorders or haemodynamic instability.
Eight patients (2.8%) were admitted for non-surgical reasons
only. Data on the 103 patients with mechanical ventilation for
longer than 48 h are presented in Table 1. The patients with
VAP (the case group) and without VAP (the control group)
who were ventilated for more than 48 h were comparable
with regard to age, sex and APACHE II scores. In the U test
the APACHE II score had a P value of 0.08, which points to
a trend of higher values in the group without VAP. Patients
with VAP had to be ventilated for a significantly longer period
(20 compared with 9 days). Their treatment in ICU was also
longer (37 compared with 18 days). In contrast with these
findings, the mortality rate was significantly higher in the
group without VAP: 25 of 54 (46.3%) patients died in the
non-VAP group, whereas only 11 of 49 (22.4%) patients
with VAP died (c2 test, P< 0.05).
Incidence and microbiology
According to CPIS criteria, a total of 60 VAPs in 49
patients were observed among 103 of the patients who
were ventilated for more than 48 h. During treatment in the
ICU, 39 patients had one VAP, nine patients had two
VAPs and one patient had three VAPs.
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Table 1
Characteristics of the 103 patients studied
Variables Patients with VAP (n = 49) Patients without VAP (n = 54)
Sex (M/F) 39/10 35/19
Age (years) 51 ± 18.5 56 ± 18 (n.s.)†
APACHE II score 11.5 ± 5 13.6 ± 6 (n.s.)†
Ventilator duration (days) (mean ± SD) 1519 (31 ± 27) 783 (14.5 ± 14)*†
Treatment on ICU (days) (mean ± SD) 1849 (37.7 ± 27) 979 (18.1 ± 15.6)*†
Cause of admission (n):
Abdominal surgery 21 25
Thoracic surgery 1 2
Aortic surgery 2 2
Other surgery 18 15
Multiple trauma 5 6
No surgery 2 4
Mortality (n)1 1 2 5 *‡
*Significant with P < 0.05; n.s., not significant but because 0.1 > P > 0.05 a trend is perceptible, which points to a distinction. †U test (Wilcoxon,
Mann and Witney). ‡c² test. VAP, ventilator-associated pneumonia; ICU, intensive care unit.The incidence was thus 24 VAPs per 100 ventilated
patients (60 of 245) or 23 VAPs per 1000 ventilator days
(60 of 2574).
Through bronchoscopic samples we found one or more
microorganisms in an amount above the threshold of the
respective methods in 54 of the 60 VAPs.
The etiological agents of the VAPs are presented in
Table 2. In 34 of the VAPs one microorganism was identi-
fied, in 18 of the VAPs two different pathogens were
found and in two cases three agents were found. Staphy-
lococcus aureus (29 cases, 37.7%), Haemophilus
influenzae and Pseudomonas aeruginosa (each 8,
10.4%),  Klebsiella sp. (7, 9.1%) and Escherichia coli (6,
7.8%) were the leading aetiologies of pulmonary infec-
tions. In six cases the bacterial cultures did not match any
of the definitions. In three of these six cases without a pos-
itive culture result, antibiotics were given at the time of
examination. All other patients were not on antibiotics at
the time of the bronchoscopy.
The elapsed times between the beginning of ventilator
treatment and the appearance of the first VAP for Gram-
positive, Gram-negative and some special microorganisms
are presented in Figure 1. Our data did not show any dif-
ference between Gram-positive and Gram-negative
pathogens with regard to the onset of infection (early-
onset compared with late-onset pneumonia). From our
data, staphylococci had an important role even in late-
onset cases and Pseudomonas aeruginosa could appear
even in early-onset cases.
For the nine patients who developed a second VAP during
their prolonged ICU stay, Pseudomonas was most fre-
quently observed (four VAPs) followed by Staphylococcus
aureus (three VAPs), Klebsiella (two VAPs), Citrobacter
freundii (one VAP) and Streptococcus pneumoniae (one
VAP).
Bronchoscopic sampling methods
Evaluation of the microbiological results for BAL and PSB
coincided with the accepted thresholds (104 CFU/ml and
103 CFU/ml). Two different thresholds were tested for the
TBS (105 CFU/ml and 106 CFU/ml) to determine which
limit was more useful.
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Table 2
Bacteriology of VAP
Species Number of cases; n = 77
Gram-positive:
Staphylococcus aureus
(among them 1 methicillin-resistant) 29 (37.7%)
Streptococcus pneumoniae 4 (5.2%)
Other streptococci 5 (6.5%)
Gram-negative:
Haemophilus influenzae 8 (10.4%)
Pseudomonas aeruginosa 8 (10.4%)
Klebsiella sp. 7 (9.1%)
Escherichia coli 6 (7.8%)
Enterobacter sp. 3 (3.9%)
Proteus sp. 3 (3.9%)
Acinetobacter sp. 1 (1.3%)
Morganella morganii 1 (1.3%)
Citrobacter freundii 1 (1.3%)
Branhamella catarrhalis 1 (1.3%)
VAP, ventilator-associated pneumonia.
Figure 1
Times until the start of ventilator-associated pneumonia (always the first episode). Circles, runaway; asterisks, extreme case.The following comparative results were found for the
quantitative microbiological data: in 54 VAP cases (90%)
both the BAL (threshold 104 CFU/ml) and the TBS
(threshold 105 CFU/ml) showed the etiological pathogens,
and the PSB (threshold 103 CFU/ml) in 50 cases (83%).
Only 30 of the 60 infections (50%) with the higher thresh-
old value in the TBS (106 CFU/ml) fulfilled the quantitative
microbiological criteria for a VAP (Table 3).
Statistical evaluation of the results of all three methods
revealed an almost complete coincidence in the results of
BAL and TBS with the lower threshold (105CFU/ml). With
the higher threshold of 106CFU/ml for TBS the coincidence
between TBS and BAL or PSB is weak. The difference in k
between PSB – TBS (105 CFU/ml) (k= 0.571) and
BAL – PSB (k = 0.741) is attributed to the different distribu-
tion in the four-square table needed for calculation (Table 4).
Discussion
VAP is a common and serious infection in ICU patients,
and is often difficult to diagnose. The difficulties of diagno-
sis are mostly a result of the following factors:
1. The possibility of multiple other causes of systemic
inflammatory reactions in these patients [10].
2. Pre-existing antibiotic usage in ICU patients.
3. The absence of a standard test to detect and diagnose
VAP [3].
In general the methods used in our study were accompanied
by a usually accepted clinical–radiological diagnosis of VAP
[2,7]. This is the deciding factor for pneumonia, because in
this setting, and perhaps generally, microbiological findings
or infiltrations in the chest X-ray alone, without clinical signs
of infection of the lung, means that there is no pneumonia. In
the control group we found definite signs of an infection or
sepsis but no signs of pulmonary infection (CPIS <6).
The incidence of VAP in our study tallies with results
reported previously [2,12,13].
The high mortality rate with regard to the APACHE II score
is probably attributable to the time of determination at
admission. The score is affected by treatment and thera-
peutic interventions and we did not investigate APACHE
scores of the patients during their ICU stay. We found a
lower mortality rate among patients with VAP (case group)
than in patients without pneumonia (control group) during
their stay in the ICU (Table 5). Opinions are divided on the
idea that VAP increases mortality rates. In a cohort study,
Bregeon  et al [9] found no increase in mortality rate
among ICU patients with VAP in comparison with those
without VAP. Other authors showed an increased mortal-
ity caused by pneumonia [14].
We believe that the basic disease – the reason for ICU
admission – must be considered to be the essential factor
responsible for mortality. This opinion is supported by the
study of Rello et al [15], who showed that severity of
illness is the most important predictor for survival of
patients in an ICU when pneumonia is diagnosed. In the
control group, more patients suffered from ultimately fatal
diseases than in the case group. In addition to the severity
of the underlying disease, 29 patients in the control group
received antibiotic therapy; it is certainly not reported, but
it is plausible, that antibiotic therapy of non-pulmonary
infections decreases the incidence of pneumonia. In these
circumstances our lower mortality rates in patients with
VAP are primarily a result of the lower severity of underly-
ing illness with adequate therapy of VAP with antibiotics.
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Table 3
Positive results of bronchoscopic methods in 60 VAPs
Method Threshold (CFU/ml) Positive cultures; n = 60 VAPs
BAL 104 56 (90%)
TBS 105 56 (90%)
PSB 103 50 (83%)
TBS 106 30 (50%)
BAL, bronchoalveolar lavage; CFU, colony-forming units; PSB,
protected specimen brush; TBS, tracheobronchial secretion; VAP,
ventilator-associated pneumonia.
Table 4
Grade of concordance by k k index
Method 1 (threshold, CFU/ml) Method 2 (threshold, CFU/ml) k Concordance
TBS (105) – BAL (104) 1.000 Nearly complete
PSB (103) – BAL (104) 0.714 Strong
TBS (105) – PSB (103) 0.571 Clear
TBS (106) – PSB (103) 0.216 Weak/poor
TBS (106) – BAL (104) 0.200 Weak/poor
BAL, bronchoalveolar lavage; CFU, colony-forming units; PSB, protected specimen brush; TBS, tracheobronchial secretion; VAP, ventilator-
associated pneumonia.The etiological pathogens found in our study represented
the microbiological situation of our ICU. Comparison with
the results of other authors is difficult because each ICU
has its specific patient population and also a specific
antibiotic policy. We find no increase in the number of
VAPs caused by typically Gram-negative bacteria with
multi-drug resistance such as Enterobacter spp. or
Pseudomonas aeruginosa.
One fundamental and contemporary aspect of our study is
noteworthy. The vast majority of our patients with VAP
were not on antibiotics at the time of bronchoscopy. This
is especially important because it is often not mentioned in
published studies. Perhaps the reason for the high fre-
quency of Gram-positive microorganisms was a more
restrictive policy on the use of antibiotics, a policy not in
place during a previous study [16] on our ICU in 1988,
when  Pseudomonas aeruginosa was the predominant
microorganism.
Our results indicate that one must consider the total spec-
trum of etiological agents during the entire period of treat-
ment. Differentiation between early-onset and late-onset
pneumonia does not seem to be justifiable [17]. However,
in second and third cases of pneumonia one must assume
a dominance of Pseudomonas aeruginosa.
Bronchoscopy has established itself as the preferred
method for collecting representative samples in our ICU,
although there is no consensus in the literature on these
invasive methods [18,19].
BAL (threshold 104 CFU/ml), PSB (threshold 103 CFU/ml)
and TBS (threshold 105 CFU/ml) were comparable in their
quantitative results. A higher threshold for TBS
(106CFU/ml) led to an unacceptable decrease in compa-
rability of results.
In conclusion, our study showed that VAP occurred 23
times for every 1000 days of mechanical ventilation
among surgical ICU patients; the prognosis of VAP was
not worse in terms of mortality in comparison with non-
infected ICU patients. Staphylococcus aureus was the
main etiological pathogen of VAP. After quantitative analy-
sis, bronchoscopic measurements including the BAL,
PSB and TBS methods produced comparable results with
a high detection rate of 90%. TBS sampling is an easy
and cheap bronchoscopic procedure that should be
investigated further.
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